[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.120.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Correspondence
July 2005

Fabry Disease: Angiokeratoma, Biomarker, and the Effect of Enzyme Replacement Therapy on Kidney Function—Reply

Arch Dermatol. 2005;141(7):904-906. doi:10.1001/archderm.141.7.905

In reply

We appreciate the comments by Ries and Schiffmann regarding our editorial.1 They are correct in stating that the use of surrogate markers in Fabry disease (FD) may produce some controversy.

In respect to angiokeratomas (AK) as a possible biomarker for disease progression as well as effect of treatment in FD, several aspects have to be taken into consideration. These include the following:

First Page Preview View Large
First page PDF preview
First page PDF preview
×